Inovio Projects Cash Runway Into Late 2027 Ahead of VOCERYQ Launch

Inovio Pharmaceuticals expects its current financial resources to fund planned operations into late Q4 2027, extending its projected cash runway beyond the planned commercial launch of VOCERYQ, its treatment for adults with recurrent respiratory papillomatosis (RRP). The forecast includes $80.5 million in net proceeds from a public offering that closed Nov. 9 and $10.9 million from warrant exercises received after Sept. 30 through Nov. 9. It also assumes about $21 million in operational net cash burn during Q4 2026. Inovio held $48.4 million in cash, cash equivalents and short-term investments as of Sept. 30. That period-end balance is separate from the later offering and warrant proceeds included in the forecast. The projection excludes VOCERYQ revenue and any future fundraising, and depends on assumptions about operations and commercialization costs. The U.S.

BeCrypto News shows a short excerpt and links to the publisher. The full report belongs to TokenPost.